# Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

> **NCT01912196** · PHASE2 · COMPLETED · sponsor: **MSI Methylation Sciences, Inc.** · enrollment: 376 (actual)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** MSI-195
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01912196
- **Lead sponsor:** MSI Methylation Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2016-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01912196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01912196, "Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01912196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*